47 results about "Benign prostatic hyperplasia (BPH)" patented technology

Computer-implemented methods for providing interactive electronic treatment assistance for benign prostatic hyperplasia and advanced prostate cancer are disclosed. The methods can include automatically sending, by a disease and disorder treatment device, an electronic pathway sign-up link to a smart mobile device. The method can include sending a plurality of inquiries about the BPH condition and / or the advanced prostate cancer condition, to the smart mobile device. The method can include receiving a plurality of patient responses from the smart mobile device. The method can include processing and storing the plurality of patient responses. The method can include providing, by the disease and disorder treatment device, patient education about various treatment therapies for advanced prostate cancer. The method can include automatically monitoring a patient having the advanced prostate cancer condition during the various treatment therapies. The method can include intervening with the various treatment therapies using the smart mobile device.

The invention relates to the technical field of biology, in particular to application of a prostate intermediate state cell and an inhibitor of the prostate intermediate state cell, and discloses application of the prostate intermediate state cell and an organ or tissue comprising the prostate intermediate state cell as a target in screening of drugs for treating prostatitis or prostatic hyperplasia. The prostate intermediate state cell inhibitor is applied to preparation of a medicine for treating prostatitis or benign prostatic hyperplasia; the inhibitor of the prostate intermediate state cells comprises one or more of a GRN signal channel inhibitor and a Sema4 signal channel agonist. The application provides a new therapeutic target for treatment of prostatitis or benign prostatic hyperplasia and drug screening, and provides a potential strategy for clinical treatment of prostatitis and benign prostatic hyperplasia.

This invention discloses the application of two dipeptides in the preparation of a diagnostic kit for differentiating prostate cancer from benign prostatic hyperplasia (BPH). The invention reveals that the combination of the dipeptides H-Asp-Phe-OH (DF) and H-Leu-Ala-OH (LA) with prostate-specific antigen (PSA) has high diagnostic value in differentiating prostate cancer from BPH, with a high accuracy rate. The combined diagnostic effect of these three peptides is significantly better than that of PSA alone in differentiating between prostate cancer and BPH, showing promise for development into a diagnostic kit for differentiating prostate cancer from BPH.

Devices and systems are disclosed for managing and / or treating body tissues obstructing a hollow body lumen, including the prostatic lobe tissues obstructing the urethra, for example conditions including benign prostatic hyperplasia (BPH), bladder outlet obstruction (BOO), benign prostatic obstruction (BPO) and associated lower urinary tract symptoms (LUTS). An implant is maintained in a constrained configuration within a distal portion of an elongated sheath so that is may be deployed by driving the implant with a pusher coaxially disposed within the sheath. An implant engaging element helps maintain control of the implant during deployment.

The application discloses application of CFHR5 protein in preparation of a kit for diagnosing and distinguishing prostate cancer and benign prostatic hyperplasia. It is found by the application that the CFHR5 protein has high diagnostic value for distinguishing prostate cancer and benign prostatic hyperplasia, the accuracy of diagnosis and distinction is high, and the CFHR5 protein has the prospect of being developed into a kit for diagnosing and distinguishing prostate cancer and benign prostatic hyperplasia.

The invention provides a bisphenol A induced rat benign prostatic hyperplasia model and a construction method, and relates to the technical field of animal models. The method comprises the following steps: S1, selecting rats which are 8-9 months old and 9-10 weeks old, and adaptively feeding the rats in a suitable environment for 7 days or more; s2, jointly applying high-fat feed and bisphenol A to the adaptively fed rats to induce benign prostatic hyperplasia; the induction time is 60-80 days, and performing biological index evaluation after the induction is completed. The exposure level of low-dose BPA adopted by the invention is closer to the actual environment exposure level of people, and a main exposure way is simulated through oral gavage. The model constructed by the method can better simulate the real process of chronic and low-dose exposure pathopoiesis of the environmental endocrine disrupter in etiology, and provides an experimental tool with more practical significance for related risk evaluation.

1. The name of the design product: hot steam treatment equipment. 2. The use of the design product: used with the prostate hot steam treatment instrument to relieve symptoms and obstruction related to benign prostatic hyperplasia (BPH). 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 1.

The invention relates to a compound as shown in a formula (I) or a salt or a solvate thereof, and also relates to a preparation method of the compound as shown in the formula (I), a pharmaceutical composition containing the compound as shown in the formula (I), and application of the compound as shown in the formula (I) or the pharmaceutical composition containing the compound as shown in the formula (I) in preparation of medicines for treating alopecia and benign prostatic hyperplasia. Through injection administration, the administration effect can be maintained for a long time, and the long-acting pharmaceutical property is ideal.

The present invention relates to a composition, a kit, and an information providing method for diagnosing prostate cancer using the methylation level of CpG regions. By using the composition, the kit, and the information providing method according to the present invention, it is possible to distinguish between prostate cancer and benign prostatic hyperplasia, and thereby diagnose prostate cancer not only quickly and accurately, but also early.

The dilatation balloon device comprises a catheter, a first balloon body, a protruding structure and a connecting piece, the catheter extends in the front-back direction, a first channel penetrating in the front-back direction is formed in the catheter, the first balloon body is arranged at the front end of the catheter, the front end of the first channel is communicated with the interior of the first balloon body, and the rear end of the first channel is communicated with a pressurizing device. The protruding structures are arranged on the outer surface of the first bag body in a protruding mode and distributed in a long shape extending in the front-back direction, in a projection view perpendicular to the front-back direction, the protruding structures are distributed on the periphery of the first bag body in a non-centrosymmetric mode, and the connecting piece is arranged at the rear end of the catheter and used for communicating the first channel with the pressurizing device. In the invention, the bulge structure can apply pressure to the affected part in a targeted manner, so that the affected part is cracked before other tissues in the bulge process of the first capsule body, and the treatment purpose is achieved. Therefore, the treatment accuracy can be improved, unnecessary tearing of healthy tissues is reduced, the complication risk is reduced, and the minimally invasive treatment requirements of diseases such as benign prostatic hyperplasia are met.

The invention provides application of TRMT61A as a target spot in preparation of a medicine for preventing or treating benign prostatic hyperplasia. The TRMT61A is specifically targeted through shRNA, pathogenic signals are blocked from the post-transcriptional level, accurate intervention on benign prostatic hyperplasia is achieved, dependence on androgen pathways is completely avoided, unavoidable sexual dysfunction and other serious side effects of traditional drugs are fundamentally avoided, and the life quality of patients is remarkably improved.

The invention provides a preparation method of the diterpenoid composition. The method comprises the following steps: extracting a rubus chingii material to obtain an extract composition; suspending the extract composition, and performing liquid-liquid extraction on the suspension to obtain a target extraction part; adsorbing and separating the target extraction part through macroporous resin, and eluting to obtain a target fraction; eluting the target fraction to obtain a target eluate; and drying the target eluate to obtain a powder product. Also provided are a diterpenoid composition obtained by the method, an oral composition comprising the diterpenoid composition, a composition comprising at least one diterpenoid extract of rubus chingii, the use of the composition in the preparation of a medicament for the treatment of benign prostatic hyperplasia (BPH) in a subject, and a method of treating BPH in a subject.

1. The name of the design product: disposable surgical instruments for treating benign prostatic hyperplasia. 2. The use of the design product: medical instruments for minimally invasive treatment of benign prostatic hyperplasia by condensing steam. 3. The design features of the design product: in shape. 4. The picture or photo that best indicates the design features: perspective view.

This invention discloses an edible fungus extract, its preparation method, and its application in the preparation of products that enhance immunity and lower lipids. The edible fungus extract is composed of Ganoderma lucidum water extract and enoki mushroom water extract. The research of this invention shows that the mixture of Ganoderma lucidum water extract and enoki mushroom water extract has the effect of synergistically enhancing immune regulation and lowering lipids, and can be added as a functional food ingredient, providing a basis for the research and development of high-value-added edible fungus products.

An embodiment relates to a sustained-release injectable composition containing dutasteride, which may exhibit a sustained dutasteride release effect for 3 months or more even when the dose of dutasteride is equal to or less than that of existing AVODART®, which is taken once a day, thereby exhibiting a long-acting drug effect by a single injection. In addition, the injectable composition may exhibit a therapeutic effect on benign prostatic hyperplasia, prostate cancer, and hair loss continuously for 3 months or more, may maintain an effective concentration of the drug at a constant level by controlling the release of the drug due to the constant average diameter of the microparticles contained in the sustained-release injectable composition, and may reduce foreign body sensation and pain when administered by injection to a patient.

The invention discloses application of idarubicin in preparation of a medicine for treating benign prostatic hyperplasia, and relates to the technical field of biological medicine. The invention discloses application of idarubicin in preparation of a medicine for treating benign prostatic hyperplasia. The application of idarubicin in BPH treatment is found and confirmed for the first time: (1) the specificity effectiveness of BPH, preferably gland proliferation type BPH, is verified, and the intervention effect of idarubicin on a core target TP63 and gland proliferation is clear; (2) the regulation and control effect on prostate volume and gland hyperplasia is supported through in-vivo experimental data; and (3) curative effect verification at a clinical level is carried out, and a clinical application path of subtype screening-drug intervention-curative effect evaluation is established, so that transformation in BPH precise treatment is facilitated. According to the research, through a complete evidence chain of cell, animal and multi-center clinical retrospective research, the treatment value of idarubicin on BPH, especially gland proliferation type BPH, is verified, and the blank in the field is filled.

The invention relates to a sustained release preparation for treating benign prostatic hyperplasia. The sustained release preparation contains silodosin and a sustained release material, the sustained-release material is a hydrophilic gel skeleton sustained-release material with the viscosity of 1000 mPa.s or above. The sustained-release preparation disclosed by the invention can realize an expected sustained-release effect in vivo.

A stable oral liquid composition of Terazosin and its pharmaceutically acceptable salt which is useful for treating symptomatic benign prostatic hyperplasia (BPH) and hypertension is disclosed. The oral liquid composition includes terazosin or a pharmaceutically acceptable salt thereof, at least one pH modifier, at least one pharmaceutically acceptable excipient, and a liquid vehicle.

This invention discloses the application of the TP63 gene or protein in the preparation of drugs for treating benign prostatic hyperplasia (BPH), belonging to the field of biomedical technology. The application of the TP63 gene or protein in the preparation of drugs for treating BPH involves precise screening of the target TP63 gene or protein based on subtype-specific proteomics data, combined with dual verification of "drugability" and "clinical relevance," enabling its transformation into a clinical drug; and possessing a complete chain of evidence for multi-cell line functional verification, fully demonstrating the effectiveness of the target intervention.

One aspect relates to a composition, a kit, and a method for detecting or isolating nucleic acids using the same. By using the composition, kit, and method for detecting or isolating nucleic acids according to one aspect, high-concentration and high-purity nucleic acids can be detected or isolated rapidly, simply, and accurately at low cost without electricity and special equipment, such as centrifugation, vacuum pumps, and heat controllers, used in conventional column and bead-based methods. Furthermore, by using the composition according to one aspect to detect or isolate one or more nucleic acids selected from the group consisting of miR-141-3p, miR-375-3P, miR-483-5P, and miR-574-3P, prostate cancer (PCa) in patients with benign prostatic hyperplasia (BPH) can be diagnosed rapidly, precisely, and early, and infectious diseases can be diagnosed rapidly, precisely, and early by detecting or isolating nucleic acids derived from microorganisms that cause infectious diseases.

The present invention is directed to methods for detecting a prostate cancer, methods for determining whether a prostate cancer is stable or progressive, low or high Gleason score, methods for differentiating benign prostate hyperplasia (BPH) from prostate cancer, methods for determining the completeness of surgery, and methods for evaluating the response to a prostate cancer therapy.

The application belongs to the field of medicine and relates to a 5alpha-reductase long-acting derivative, a preparation method and use thereof, a compound shown in formula (I) or a salt thereof, a preparation method of the compound of formula (I), and use of the compound of formula (I) or a pharmaceutical composition containing the compound of formula (I) in the preparation of a drug for treating alopecia and benign prostatic hyperplasia. The application can maintain the administration effect for a long time through injection administration, has the characteristics of significant long-acting and ideal pharmaceutical technical properties.

Disclosed is a “benign prostatic hyperplasia surgical device using an anchor assembly and a needle. The benign prostatic hyperplasia surgical device includes a plurality of anchors disposed on the prostate gland compressing the urethra and a ligature thread connecting the plurality of anchors to each other so that the plurality of anchors continuously compress prostatic tissues to allow the urethra to be open. Further, the benign prostatic hyperplasia surgical device of the present invention includes: an elastic needle receiving the plurality of anchors therein and inserted into the urethra to guide the plurality of anchors and the ligature thread so that the plurality of anchors and the ligature thread are located on the prostate gland; and a needle launching means for launching the needle so that the needle is inserted into the urethra to allow the plurality of anchors and the ligature thread to be discharged through the needle.

The application provides a meridian-targeting theory-based traditional Chinese medicine preparation for treating prostatitis and a preparation method thereof. The preparation is composed of eighteen kinds of traditional Chinese medicines, including plantago seed, alisma orientalis, phellodendron, taraxacum, salvia miltiorrhiza, cyathula officinalis, eucommia ulmoides and epimedium etc. The cyathula officinalis, plantago seed and alisma orientalis are used as meridian-leading drugs to guide the active ingredients to flow down along the liver meridian of foot-Jueyin, the kidney meridian of foot-Shaoyin and the bladder meridian of foot-Taiyang, and target the prostate region. The whole preparation has the effects of clearing heat and reducing dampness, promoting blood circulation to remove blood stasis, soothing liver and regulating qi and tonifying kidney and consolidating the foundation, and is suitable for chronic prostatitis and benign prostatic hyperplasia of the type of lower-heat and kidney deficiency and blood stasis. The preparation can be prepared into various dosage forms such as capsules, granules and oral liquid. Experiments show that the preparation can significantly improve the urination symptoms and reduce the inflammation and fibrosis of the prostate, and has the advantages of strong targeting, definite curative effect, high safety and long-term use.

The invention discloses an application of a TGF (Transforming Growth Factor)-beta 1 inhibitor in preparing a medicine for treating benign prostatic hyperplasia. According to the application disclosed by the invention, signal path analysis and the like are carried out on single cell sequencing data of fibroblasts of a large prostate (from a benign prostatic hyperplasia group) and a small prostate (from a bladder neck contracture group), so that a remarkable endothelial-mesenchymal transition (EndMT) phenomenon is observed in the fibroblasts of the large prostate for the first time; the EndMT phenomenon is jointly driven by a transforming growth factor TGF-beta1 and a vascular endothelial growth factor VEGF, wherein the TGF-beta1 is a main inducible factor. Therefore, drugs at least acting on the TGF-beta1 target are designed and found to inhibit the EndMT phenomenon in the prostatic hyperplasia and play a role in treating benign prostatic hyperplasia (BPH). Finally, experiments prove that the TGF-beta1 inhibitor (such as tranilast and asiaticoside) can reduce the volume of prostate and improve urinary symptoms and sexual functions, has no obvious toxic and side effects, and can be used for preparing BPH treatment drugs.

The present invention relates to a composition for preventing, ameliorating or treating benign prostatic hyperplasia, containing Hovenia dulcis honey as an active ingredient. Specifically, the Hovenia dulcis honey of the present invention suppresses the proliferation of prostate cells that are hyperproliferated by dihydrotestosterone (DHT), which is a male hormone, and has the effect of reducing prostate weight in an animal model with induced benign prostatic hyperplasia, and thus can be effectively used as a composition for preventing, ameliorating or treating benign prostatic hyperplasia.

The invention relates to application of a sarsasapogenin structure derivative in preparation of a medicine for treating benign prostatic hyperplasia, prostatitis and / or sexual dysfunction. The structural formula of the sarsasapogenin structure derivative is shown in the specification. According to the application of the sarsasapogenin structure derivative in preparation of medicines for treating benign prostatic hyperplasia, prostatitis and sexual dysfunction, a testosterone propionate induced prostatic hyperplasia model can prove that the small molecule compound has a good effect of treating the prostatic hyperplasia; the molecular intervention effect in prostatitis microenvironment regulation and control can prove that the small molecule compound has a good prostatitis treatment effect, has potential huge value in treatment of benign prostatic hyperplasia, prostatitis and sexual dysfunction, and meanwhile has important scientific and commercial application value.

This invention relates to the field of biomedicine, specifically disclosing an antibody for treating benign prostatic hyperplasia (BPH) and its applications. The antibody is a nanobody containing a complementary determinant region (CDR) sequence as shown in SEQ ID NO:5. This invention provides a method for preparing the antibody and demonstrates that it effectively antagonizes the binding of GnRH to GnRHR, thereby inhibiting cAMP production mediated by the GnRH signaling pathway and reducing the levels of testosterone, dihydrotestosterone, and luteinizing hormone. In vivo pharmacodynamic experiments show that the antibody provided by this invention can significantly improve the prostate weight / body weight ratio in a rat model of benign prostatic hyperplasia, exhibiting a good therapeutic effect on BPH and providing a new candidate drug for the clinical treatment of BPH.

The application discloses a rat benign prostatic hyperplasia model, a building method and application thereof, and belongs to the technical field of animal models. The building method comprises the following steps: D-galactose and testosterone undecanoate are jointly administered to rats in adaptive feeding to induce benign prostatic hyperplasia; the induction time is 60 days, D-galactose with a dosage of 125mg / kg / d-500mg / kg / d is continuously given to the rats by subcutaneous injection within 60 days, and testosterone undecanoate olive oil solution with a dosage of 15mg / kg / 10d is given to the rats by intraperitoneal injection starting from the 30th day. The prostate index of the rat benign prostatic hyperplasia model induced by D-galactose and testosterone undecanoate, serum hormone levels, histopathology, androgen receptor and proliferation-related molecules and testicular function are detected to comprehensively evaluate the effectiveness and practicability of the model, and the results show that the rat prostatic hyperplasia model induced by aging and androgen in the application is more close to the pathogenic characteristics of clinical benign prostatic hyperplasia.